ARTICLE | Company News

Bristol-Myers, University of Texas MD Anderson Cancer Center deal

October 13, 2014 7:00 AM UTC

Bristol-Myers partnered with the center to evaluate the pharma's Opdivo nivolumab, Yervoy ipilimumab and three undisclosed clinical stage immuno-oncology compounds separately and in combination. MD Anderson will run up to 10 Phase I and II trials using the BMS compounds as monotherapies and in combinations to treat acute and chronic leukemia, as well as other hematologic malignancies. A joint development committee will oversee the collaboration activities. ...